2,971 results match your criteria Breast Cancer Res.[Journal]


Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.

Breast Cancer Res 2020 May 28;22(1):58. Epub 2020 May 28.

Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign breast lesions. However, it is unclear if they have any efficacy as prognostic imaging markers. The aim of this study was to investigate the relationship between ultrafast DCE-MRI-derived kinetic parameters and breast cancer characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01292-9DOI Listing

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.

Breast Cancer Res 2020 May 28;22(1):56. Epub 2020 May 28.

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Background: Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting. We aimed to prospectively compare the risk of early progression according to circulating ESR1 mutations, CA-15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01290-xDOI Listing

A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.

Breast Cancer Res 2020 May 28;22(1):57. Epub 2020 May 28.

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of our study was to develop and validate a radiomics classifier that classifies breast cancer pCR post-NAC on MRI prior to surgery.

Methods: This retrospective study included women treated with NAC for breast cancer from 2014 to 2016 with (1) pre- and post-NAC breast MRI and (2) post-NAC surgical pathology report assessing response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01291-wDOI Listing

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.

Breast Cancer Res 2020 05 28;22(1):55. Epub 2020 May 28.

UVSQ, Université Paris-Saclay, Saint Cloud, France.

Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France).

Methods: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01293-8DOI Listing

Modeling the natural history of ductal carcinoma in situ based on population data.

Breast Cancer Res 2020 May 27;22(1):53. Epub 2020 May 27.

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Background: The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the absence of biopsy or complete excision.

Methods: Two well-established population models evaluated six possible DCIS natural history submodels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01287-6DOI Listing

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.

Breast Cancer Res 2020 May 27;22(1):54. Epub 2020 May 27.

Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, South Korea.

Introduction: Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT) with NET in pre-menopausal breast cancer.

Patients And Methods: In this prospective, randomised, phase III study, oestrogen receptor (ER)-positive, HER2-negative, and lymph node-positive pre-menopausal breast cancer patients were recruited from 7 hospitals in South Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01288-5DOI Listing

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Breast Cancer Res 2020 May 20;22(1):52. Epub 2020 May 20.

The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA.

An amendment to this paper has been published and can be accessed via the original article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01294-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238734PMC

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

Breast Cancer Res 2020 May 19;22(1):51. Epub 2020 May 19.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Background: The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well as with tamoxifen, fulvestrant, exemestane, and exemestane plus everolimus in a letrozole-resistant MCF7 model (MCF7LR).

Methods: MCF7AC1 tumor-bearing mice were randomized to control (no drug), letrozole (10 μg/day), tamoxifen (500 μg/day), or Z-endoxifen (25 and 75 mg/kg). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01286-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238733PMC

ERα-36 regulates progesterone receptor activity in breast cancer.

Breast Cancer Res 2020 May 19;22(1):50. Epub 2020 May 19.

Université de Lyon, F-69000, Lyon, France.

Background: Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast cancer (BC). The recent identification of ERα-36, a splice variant of ERα, has uncovered a new facet of this pathology. Although ERα-36 expression is associated with poor prognosis, metastasis development, and resistance to treatment, its predictive value has so far not been associated with a BC subtype and its mechanisms of action remain understudied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01278-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238515PMC

Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.

Breast Cancer Res 2020 May 15;22(1):49. Epub 2020 May 15.

Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center, MBC#03, Riyadh, 11211, Saudi Arabia.

Background: Most breast cancer-associated fibroblasts (CAFs) are active and important cancer-promoting cells, with significant impact on patient prognosis. Therefore, we investigated here the role of the protein kinase ATR in breast stromal fibroblasts in the prognosis of locally advanced breast cancer patients.

Methods: We have used immunohistochemistry to assess the level of ATR in breast cancer tissues and their adjacent normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01289-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229635PMC

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Breast Cancer Res 2020 May 15;22(1):48. Epub 2020 May 15.

Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, 77030, USA.

Background: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. This study investigated the effects of Pan-HER (Symphogen, Ballerup, Denmark), a novel mixture of six monoclonal antibodies directed against members of the HER family EGFR, HER2, and HER3, in a preclinical trial of TNBC patient-derived xenografts (PDXs).

Methods: Fifteen low passage TNBC PDX tumor samples were transferred into the right mammary fat pad of mice for engraftment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01280-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227035PMC

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.

Breast Cancer Res 2020 May 14;22(1):46. Epub 2020 May 14.

Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.

Background: The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of TILs is less clear in luminal breast cancer. Here, we in postmenopausal patients with primary oestrogen receptor-positive (ER+), HER2 normal, operable breast cancer assessed the importance of inducing TILs during 4 months of letrozole on response in a neoadjuvant phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01285-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222485PMC

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.

Breast Cancer Res 2020 May 14;22(1):47. Epub 2020 May 14.

West German Study Group, Mönchengladbach, Germany.

Background: The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-infiltrating lymphocyte (TIL) measurements correlate with genomic measurements such as the Oncotype DX Recurrence Score® and (ii) whether the survival impact of TIL measurements varies according to different adjuvant systemic therapies.

Methods: The WSG PlanB trial compared an anthracycline-free chemotherapy regimen (6x docetaxel/cyclophosphamide, TC) to an anthracycline-taxane sequence (4xEC followed by 4x docetaxel) in patients with intermediate-risk, HER2-negative early breast cancer (EBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01283-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227091PMC

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

Breast Cancer Res 2020 May 13;22(1):45. Epub 2020 May 13.

Department of Medical Oncology, Hospital Clinic of Barcelona, Villarroel 170, 08035, Barcelona, Spain.

Purpose: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01284-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222307PMC

Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.

Breast Cancer Res 2020 May 11;22(1):43. Epub 2020 May 11.

Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Bldg 560, Room 32-33, 1050 Boyles Street, Frederick, MD, 21702, USA.

Next-generation sequencing of Sri Lankan families with inherited cancer syndromes resulted in the identification of five BRCA2 variants of unknown clinical significance. Interpreting such variants poses significant challenges for both clinicians and patients. Using a mouse embryonic stem cell-based functional assay, we found I785V, N830D, and K2077N to be functionally indistinguishable from wild-type BRCA2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01272-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216543PMC

Insulin resistance contributes to racial disparities in breast cancer prognosis in US women.

Breast Cancer Res 2020 May 12;22(1):40. Epub 2020 May 12.

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the link between race and poor prognosis in breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01281-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216707PMC

Investigation of the adolescent female breast transcriptome and the impact of obesity.

Breast Cancer Res 2020 May 11;22(1):44. Epub 2020 May 11.

Clinical Research Branch, National Institute of Environmental Health Sciences, 111 TW Alexander Drive, MD A2-03, Research Triangle Park, NC, 27709, USA.

Background: Early life environmental exposures affect breast development and breast cancer risk in adulthood. The breast is particularly vulnerable during puberty when mammary epithelial cells proliferate exponentially. In overweight/obese (OB) women, inflammation increases breast aromatase expression and estrogen synthesis and promotes estrogen-receptor (ER)-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01279-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216667PMC

Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients.

Breast Cancer Res 2020 May 6;22(1):42. Epub 2020 May 6.

Division of Pathology, Singapore General Hospital, 20 College Road, Academia, Level 7, Diagnostics Tower, Singapore, 169856, Singapore.

Background: Stromal and collagen biology has a significant impact on tumorigenesis and metastasis. Collagen is a major structural extracellular matrix component in breast cancer, but its role in cancer progression is the subject of historical debate. Collagen may represent a protective layer that prevents cancer cell migration, while increased stromal collagen has been demonstrated to facilitate breast cancer metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01282-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204022PMC

In utero estrogenic endocrine disruption alters the stroma to increase extracellular matrix density and mammary gland stiffness.

Breast Cancer Res 2020 May 5;22(1):41. Epub 2020 May 5.

Department of Molecular Genetics, The Ohio State University, 920 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA.

Background: In utero endocrine disruption is linked to increased risk of breast cancer later in life. Despite numerous studies establishing this linkage, the long-term molecular changes that predispose mammary cells to carcinogenic transformation are unknown. Herein, we investigated how endocrine disrupting compounds (EDCs) drive changes within the stroma that can contribute to breast cancer susceptibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01275-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201668PMC

Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.

Breast Cancer Res 2020 May 1;22(1):39. Epub 2020 May 1.

Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota Masonic Cancer Center, Delivery Code 2812 Cancer and Cardiovascular Research Building; Suite 3-126 2231 6th St SE, Minneapolis, MN, 55455, USA.

Background: Altered signaling pathways typify breast cancer and serve as direct inputs to steroid hormone receptor sensors. We previously reported that phospho-Ser134-GR (pS134-GR) species are elevated in triple-negative breast cancer (TNBC) and cooperate with hypoxia-inducible factors, providing a novel avenue for activation of GR in response to local or cellular stress.

Methods: We probed GR regulation by factors (cytokines, growth factors) that are rich within the tumor microenvironment (TME). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01277-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193415PMC

Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells.

Breast Cancer Res 2020 Apr 22;22(1):38. Epub 2020 Apr 22.

INSERM N2C UMR1069, University of Tours, 37032, Tours, France.

Background: The highest incidence of breast cancer is in the Western world. Several aspects of the Western lifestyle are known risk factors for breast cancer. In particular, previous studies have shown that cholesterol levels can play an important role in the regulation of tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01276-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178965PMC

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.

Breast Cancer Res 2020 Apr 15;22(1):36. Epub 2020 Apr 15.

Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.

Background: Multigene panels are routinely used to assess for predisposing germline mutations in families at high breast cancer risk. The number of variants of unknown significance thereby identified increases with the number of sequenced genes. We aimed to determine whether tumor sequencing can help refine the analysis of germline variants based on second somatic genetic events in the same gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01273-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161277PMC

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.

Breast Cancer Res 2020 Apr 15;22(1):37. Epub 2020 Apr 15.

Department of Oncology, Karmanos Cancer Institute Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA.

Background: At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGFR, which is enhanced by Src activation. Attenuation of Src reversed nuclear translocation, restoring EGFR to the cell surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01270-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160960PMC

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.

Breast Cancer Res 2020 Mar 23;22(1):31. Epub 2020 Mar 23.

Department of Microbiology, Immunology and Genetics, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA.

After publication of the original article [1], we were notified that the wrong version of Fig. 2b has been published. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01268-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087376PMC

Letter to the editor: Response to Giardiello D, Antoniou AC, Mariani L, Easton DF, Steyerberg EW.

Breast Cancer Res 2020 Apr 10;22(1):35. Epub 2020 Apr 10.

Department of Clinical Research, Faculty of Medicine, University of Basel, Missionstrasse 64, 2 OG - Room 007, 4055, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01274-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146948PMC

Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment.

Breast Cancer Res 2020 Apr 9;22(1):34. Epub 2020 Apr 9.

Molecular Skeletal Biology Laboratory, Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background: Osteoclast activation is a hallmark of breast cancer-induced bone disease while little is known about the role of osteoblasts in this process. Recently, we identified the homeodomain protein TG-interacting factor-1 (Tgif1) as a crucial regulator of osteoblast function. In this study, we demonstrate that lack of Tgif1 also restricts the progression of breast cancer bone metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01269-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146874PMC

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.

Breast Cancer Res 2020 04 6;22(1):33. Epub 2020 Apr 6.

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133, Milan, Italy.

Background: The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2- mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase inhibitor (AI) exemestane has become a standard treatment for patients with HR+ HER2- mBC resistant to prior non-steroidal AI therapy. In the recent SOLAR-1 trial, the inhibitor of the PI3K alpha subunit (p110α) alpelisib in combination with fulvestrant prolonged progression-free survival (PFS) when compared to fulvestrant alone in patients with PIK3CA-mutated HR+ HER2- mBC that progressed after/on previous AI treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01271-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137211PMC

Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.

Breast Cancer Res 2020 03 26;22(1):32. Epub 2020 Mar 26.

Department of Pathology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.

Background: The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition of tumor-infiltrating lymphocyte (TIL) subsets and PD-L1+ immune cells and to compare it with that of invasive breast cancer.

Materials And Methods: A total of 671 cases including three different disease groups of pure DCIS, DCIS with microinvasion (DCIS-M), and invasive carcinoma were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01267-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098119PMC

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.

Breast Cancer Res 2020 03 18;22(1):30. Epub 2020 Mar 18.

Department of Medical Oncology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

Background: Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast cancer management. The hepatocyte growth factor (HGF)/c-MET axis and the stromal cell-derived factor-1 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) axis are prognostic in women with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01266-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081628PMC

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

Breast Cancer Res 2020 03 13;22(1):29. Epub 2020 Mar 13.

Department of Biomedical Engineering, Boston University, 44 Cummington Mall, Boston, MA, 02215, USA.

Background: Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedback about treatment response at the earliest stages of therapy to identify patients likely to benefit from changing treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01262-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071774PMC

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.

Breast Cancer Res 2020 03 12;22(1):27. Epub 2020 Mar 12.

David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

Background: Palbociclib improves outcomes for women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). Dose reductions are recommended for the management of hematologic toxicities. A previous pooled analysis from the PALOMA clinical trials showed that 36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01263-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068918PMC

Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.

Breast Cancer Res 2020 03 12;22(1):28. Epub 2020 Mar 12.

The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan, Israel.

After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the patients 1-8 are repeated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01265-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068888PMC

MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

Breast Cancer Res 2020 03 6;22(1):26. Epub 2020 Mar 6.

Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, 87 Ding Jiaqiao Rd., Nanjing, 210009, China.

Background: Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown.

Methods: We examined miR-7 expression in breast cancer and developed a BCSC-driven xenograft mouse model, to evaluate the effects of miR-7 overexpression on the decrease of the BCSC subset in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01264-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060548PMC

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res 2020 Feb 26;22(1):25. Epub 2020 Feb 26.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.

After publication of the original article [1], we were notified that columns in Table 2 were erroneously displayed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01259-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045606PMC
February 2020

Lower vitamin D status may help explain why black women have a higher risk of invasive breast cancer than white women.

Authors:
William B Grant

Breast Cancer Res 2020 02 21;22(1):24. Epub 2020 Feb 21.

Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01261-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033921PMC
February 2020

Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort.

Breast Cancer Res 2020 02 19;22(1):23. Epub 2020 Feb 19.

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.

Background: Experimental and epidemiological studies demonstrate a role for 27-hydroxycholesterol (27HC) in breast cancer development, though results are conflicting. Cholesterol 27-hydroxylase (CYP27A1) and oxysterol 7-alpha-hydroxylase (CYP7B1) regulate 27HC concentrations, while differential expression of the liver X receptor (LXR) and estrogen receptor beta (ERβ) may impact the association between 27HC and breast cancer risk.

Methods: We evaluated correlates of tumor tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ and the association between circulating prediagnostic 27HC concentrations and breast cancer risk by marker expression in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort including 287 breast cancer cases with tumor tissue available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1253-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031866PMC
February 2020

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.

Breast Cancer Res 2020 02 18;22(1):22. Epub 2020 Feb 18.

University of Alabama at Birmingham, Birmingham, AL, USA.

Background: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting.

Methods: Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01258-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027068PMC
February 2020

Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.

Breast Cancer Res 2020 02 17;22(1):21. Epub 2020 Feb 17.

Parkville Integrated Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.

Polygenic factors are estimated to account for an additional 18% of the familial relative risk of breast cancer, with those at the highest level of polygenic risk distribution having a least a twofold increased risk of the disease. Polygenic testing promises to revolutionize health services by providing personalized risk assessments to women at high-risk of breast cancer and within population breast screening programs. However, implementation of polygenic testing needs to be considered in light of its current limitations, such as limited risk prediction for women of non-European ancestry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-01260-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026946PMC
February 2020

Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.

Breast Cancer Res 2020 02 11;22(1):19. Epub 2020 Feb 11.

Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK.

As a consequence of responding to colleagues who asked about the publication of the original article [1], the authors have determined that the data published in Table 4 of the paper are incorrect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1257-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014730PMC
February 2020

Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype.

Breast Cancer Res 2020 02 11;22(1):18. Epub 2020 Feb 11.

Department of Epidemiology and Biostatistics, SUNY Downstate Health Sciences University School of Public Health, Brooklyn, NY, USA.

Background: The molecular mechanisms underlying the association between increased adiposity and aggressive breast cancer phenotypes remain unclear, but likely involve the adipokines, leptin (LEP) and adiponectin (ADIPOQ), and their receptors (LEPR, ADIPOR1, ADIPOR2).

Methods: We used immunohistochemistry (IHC) to assess LEP, LEPR, ADIPOQ, ADIPOR1, and ADIPOR2 expression in breast tumor tissue microarrays among a sample of 720 women recently diagnosed with breast cancer (540 of whom self-identified as Black). We scored IHC expression quantitatively, using digital pathology analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1256-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014630PMC
February 2020

Letter to the editor: a response to Ming's study on machine learning techniques for personalized breast cancer risk prediction.

Breast Cancer Res 2020 02 10;22(1):17. Epub 2020 Feb 10.

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1255-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011440PMC
February 2020

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.

Breast Cancer Res 2020 02 3;22(1):16. Epub 2020 Feb 3.

The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan, Israel.

Background: Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10-50%) in metastatic, endocrine therapy-resistant cancers and are associated with a shorter progression-free survival. Little is known about the incidence and clinical implication of these mutations in early recurrence events, such as local recurrences or newly diagnosed metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1246-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998824PMC
February 2020

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Breast Cancer Res 2020 Jan 31;22(1):14. Epub 2020 Jan 31.

Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK.

After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1254-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993431PMC
January 2020

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates.

Breast Cancer Res 2020 01 31;22(1):15. Epub 2020 Jan 31.

Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.

Background: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).

Methods: Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.

Results: We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1252-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995165PMC
January 2020

Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.

Breast Cancer Res 2020 01 31;22(1):13. Epub 2020 Jan 31.

Division of Medical Oncology, Maastricht University Medical Center, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.

Background: In patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters are used for risk prediction. DNA methylation markers have been proven to be of additional prognostic value in several cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1250-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993426PMC
January 2020

A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.

Breast Cancer Res 2020 01 28;22(1):12. Epub 2020 Jan 28.

ImmunityBio, 2901 Mission St. Ext., Santa Cruz, CA, 95066, USA.

Background: Breast cancer intrinsic molecular subtype (IMS) as classified by the expression-based PAM50 assay is considered a strong prognostic feature, even when controlled for by standard clinicopathological features such as age, grade, and nodal status, yet the molecular testing required to elucidate these subtypes is not routinely performed. Furthermore, when such bulk assays as RNA sequencing are performed, intratumoral heterogeneity that may affect prognosis and therapeutic decision-making can be missed.

Methods: As a more facile and readily available method for determining IMS in breast cancer, we developed a deep learning approach for approximating PAM50 intrinsic subtyping using only whole-slide images of H&E-stained breast biopsy tissue sections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1248-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988279PMC
January 2020

Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis.

Breast Cancer Res 2020 01 28;22(1):11. Epub 2020 Jan 28.

Department of Microbiology, Immunology and Genetics, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA.

Background: Limited information is available on biomarker(s) for triple-negative breast cancer (TNBC) that can address the higher incidence and aggressiveness of TNBC in African-American (AA) women. Our previous studies have demonstrated annexin A2 (AnxA2) association with exosomes which promotes angiogenesis and metastasis. Therefore, our goal was to examine the expression and function of exosomal-annexin A2 (exo-AnxA2) derived from the serum samples of breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1251-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986157PMC
January 2020

Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort.

Breast Cancer Res 2020 01 22;22(1):10. Epub 2020 Jan 22.

Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.

Background: Adjuvant radiotherapy (RT) for breast cancer (BC) has been associated with an increased risk of ischemic heart disease (IHD). We examined the incidence of IHD in a large population-based cohort of women with BC.

Methods: The Breast Cancer DataBase Sweden (BCBaSe) includes all women diagnosed with BC from 1992 to 2012 (n = 60,217) and age-matched women without a history of BC (n = 300,791) in three Swedish health care regions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1249-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977272PMC
January 2020

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.

Breast Cancer Res 2020 01 16;22(1). Epub 2020 Jan 16.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, CBI 8RN, UK.

Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-020-1247-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966793PMC
January 2020